Silence Therapeutics plc Silence Therapeutics plc

Silence Therapeutics plc

SLN

Rank in Stocks #8284
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Share Price
$19.83
Last synced: 2026-11-13
Market Cap
$1.09B
Change (1 day)
0.15%
Change (1 year)
190.34%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Silence Therapeutics plc (SLN)
EPS as of September 2026 TTM: $-2.73
According to Silence Therapeutics plc's latest financial reports, its current EPS (TTM) is $-2.73. At the end of 2025 the company had an EPS of $-5.67, a decrease compared to its 2024 EPS of $-2.97.
EPS history for Silence Therapeutics plc from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-2.73 -51.85%
2025 $-5.67 90.66%
2024 $-2.97 -32.87%
2023 $-4.43 -3.13%
2022 $-4.57 150.55%
2021 $-1.83 20.27%
2020 $-1.52 46.73%
2019 $-1.03 4.11%
2018 $-0.99 960.30%
2017 $-0.09 -78.91%
2016 $-0.44 0.50%
2015 $-0.44 -57.01%
2014 $-1.03 3.48%
2013 $-0.99 -84.65%
2012 $-6.47 139.69%
2011 $-2.70 -58.69%
2010 $-6.54 -44.13%
2009 $-11.70 -8.19%
2008 $-12.75 8.23%
2007 $-11.78 15.71%
2006 $-10.18 -28.58%
2005 $-14.25 -52.93%
2004 $-30.27 18.11%
2003 $-25.63 70.52%
2002 $-15.03 -25.08%
2001 $-20.06 5.14%
2000 $-19.08 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -67.40%
US
$15.66 -673.63%
US
$-7.07 158.97%
US
$-5.29 93.77%
AU
$12.73 -566.38%
BE

Questions about Silence Therapeutics plc's earnings per share (EPS)

What is Silence Therapeutics plc's earnings per share (EPS)?

Silence Therapeutics plc's earnings per share (EPS) over the last twelve months is $-2.73, as of Sep 2026.

What was Silence Therapeutics plc's earnings per share (EPS) in 2025?

In 2025, Silence Therapeutics plc's earnings per share (EPS) was $-5.67, compared with $-2.97 in 2024.

How has Silence Therapeutics plc's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Silence Therapeutics plc's earnings per share (EPS) was highest in 2020 ($-1.52) and lowest in 2025 ($-5.67).

How does Silence Therapeutics plc's earnings per share (EPS) compare with similar companies?

Silence Therapeutics plc's earnings per share (EPS) ($-2.73) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.